Company profile LGVN
There is not enough data for Longeveron -stock to provide analysis
There is not enough data for Longeveron -stock to provide correlation calculation
There is not enough data for Longeveron -stock to provide analysis
There is not enough data for Longeveron clinical trials to provide analysis
There is not enough data for Longeveron clinical trials to provide correlation calculation
There is not enough data for Longeveron clinical trials to provide analysis
There is not enough data for LOMECEL-B therapy to provide analysis
There is not enough data for LOMECEL-B therapy to provide correlation calculation
There is not enough data for LOMECEL-B therapy to provide analysis
There is not enough data for allogeneic medicinal signaling cell therapy to provide analysis
There is not enough data for allogeneic medicinal signaling cell therapy to provide correlation calculation
There is not enough data for allogeneic medicinal signaling cell therapy to provide analysis
There is not enough data for aging-related frailty treatment to provide analysis
There is not enough data for aging-related frailty treatment to provide correlation calculation
There is not enough data for aging-related frailty treatment to provide analysis
After 38 days of this quarter the interest is at 45.0. Based on that we can calculate that during remaining 53 days it will total up to 108.0. Alzheimer's disease therapy expected interest is significantly higher compared to same quarter last year (+116.0%) but lower than previous quarter (-52.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 135 | 59 -56.3% QoQ | 87 47.5% QoQ | 104 19.5% QoQ |
| 2020 | 67 -50.4% YoY -35.6% QoQ | 125 111.9% YoY 86.6% QoQ | 181 108.0% YoY 44.8% QoQ | 121 16.3% YoY -33.1% QoQ |
| 2021 | 124 85.1% YoY 2.5% QoQ | 77 -38.4% YoY -37.9% QoQ | 56 -69.1% YoY -27.3% QoQ | 106 -12.4% YoY 89.3% QoQ |
| 2022 | 90 -27.4% YoY -15.1% QoQ | 71 -7.8% YoY -21.1% QoQ | 78 39.3% YoY 9.9% QoQ | 30 -71.7% YoY -61.5% QoQ |
| 2023 | 50 -44.4% YoY 66.7% QoQ | 85 19.7% YoY 70.0% QoQ | 106 35.9% YoY 24.7% QoQ | 226 653.3% YoY 113.2% QoQ |
| 2024 | 45 -10.0% YoY -80.1% QoQ | - | - | - |
The average 5 years interest of Alzheimer's disease therapy was 7.78 per week. The last year interest of Alzheimer's disease therapy compared to the last 5 years has changed by 26.61%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 21.31%.
After 38 days of this quarter the interest is at 96.0. Based on that we can calculate that during remaining 53 days it will total up to 230.0. acute respiratory distress syndrome treatment expected interest is significantly higher compared to previous quarter (+91.7%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 39 | 250 541.0% QoQ | 114 -54.4% QoQ | 86 -24.6% QoQ |
| 2020 | 115 194.9% YoY 33.7% QoQ | 33 -86.8% YoY -71.3% QoQ | 204 78.9% YoY 518.2% QoQ | 230 167.4% YoY 12.7% QoQ |
| 2021 | 72 -37.4% YoY -68.7% QoQ | 77 133.3% YoY 6.9% QoQ | 61 -70.1% YoY -20.8% QoQ | 29 -87.4% YoY -52.5% QoQ |
| 2022 | 165 129.2% YoY 469.0% QoQ | 78 1.3% YoY -52.7% QoQ | 100 63.9% YoY 28.2% QoQ | 187 544.8% YoY 87.0% QoQ |
| 2023 | 165 0.0% YoY -11.8% QoQ | 62 -20.5% YoY -62.4% QoQ | 233 133.0% YoY 275.8% QoQ | 120 -35.8% YoY -48.5% QoQ |
| 2024 | 96 -41.8% YoY -20.0% QoQ | - | - | - |
The average 5 years interest of acute respiratory distress syndrome treatment was 9.68 per week. The last year interest of acute respiratory distress syndrome treatment compared to the last 5 years has changed by 21.8%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 19.94%.
Google Trends for hypoplastic left heart syndrome therapy
Not enough data for reliable calculations!
There is not enough data for hypoplastic left heart syndrome therapy to provide analysis
There is not enough data for hypoplastic left heart syndrome therapy to provide correlation calculation
There is not enough data for hypoplastic left heart syndrome therapy to provide analysis
There is not enough data for Longeveron contact to provide analysis
There is not enough data for Longeveron contact to provide correlation calculation
There is not enough data for Longeveron contact to provide analysis
There is not enough data for Longeveron website to provide analysis
There is not enough data for Longeveron website to provide correlation calculation
There is not enough data for Longeveron website to provide analysis
There is not enough data for Longeveron headquarters to provide analysis
There is not enough data for Longeveron headquarters to provide correlation calculation
There is not enough data for Longeveron headquarters to provide analysis